A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease
A Multicenter, Randomized, Open-label, Phase 2 Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease, Who Has Previously Treated With rhEPO and Maintains the Hemoglobin in a Stabilize State
Sponsor: First Affiliated Hospital of Zhejiang University
This PHASE2 trial investigates Renal Anemia of Chronic Kidney Disease and is currently completed. First Affiliated Hospital of Zhejiang University leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jun 2021 — Jan 2023 [monthly]
Recruiting PHASE2
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital of Zhejiang University
- Xiamen Amoytop Biotech Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changsha, China , Chengdu, China , Chongqing, China , Dalian, China , Guangzhou, China , Guanzhou, China , Hangzhou, China , Hohhot, China , Huai'an, China and 4 more locations